🔗 Share this article

While America undertakes sweeping adjustments to its immunization guidelines, a particular individual has surfaced in a surprising turn: Høeg, an American of Danish descent physician and epidemiologist who initially gained attention by expressing skepticism about coronavirus vaccines throughout the global health crisis and has focused upon potential deaths following Covid vaccination in her recent time at the Food and Drug Administration.

Planned Changes to Childhood Immunization Program

Public health authorities were set to unveil sweeping changes to the childhood vaccine schedule earlier this month, aligning the US with the Danish national calendar, according to reports – a significant shift that would put the US at odds with many the international standard with insufficient data for public health gain. The planned update has been delayed until the new year.

Rather than the top vaccines chief, Høeg is scheduled to address the audience at the event. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth person to lead the office this calendar year.

Consolidating Power at the FDA

Høeg's temporary position may indicate a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Dr. Prasad solidify control at the regulatory agency – and it points to a greater focus upon rolling back long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing some pediatric shot schedules in the US to become more similar to the Danish model, a country with comprehensive healthcare and a number of inhabitants about the size of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on vaccination policy – traditionally the purview of Prasad, head of the FDA’s CBER – as opposed to drug regulation.

Concerns Over Background

The appointee has no apparent track record in medication creation, oversight or leadership, which has been typical for former heads of the biologics center. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have the necessary background” for running the drug-regulation department, said Jonathan Howard. “She’s never run a clinical trial. She is not versed in running a major agency. She lacks background in pharmaceutical oversight.”

Previous directors of CBER would “be deeply familiar with legal statutes and the research of drug development”, noted a former acting FDA commissioner. “Frankly, she doesn’t have the sort of resume that prior appointees who ran CBER have had.”

This division has an immense portfolio at the agency, Woodcock pointed out.

“Everybody just focuses on the innovative therapies, but the generic drug division authorizes thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and so forth, and each of these have to be managed,” she noted. “The responsibility you neglect, that’s the thing that I always told people is going to cause problems.”

There is also, a substantial management component to the role, which supervises more than 5,000 staff members. “It’s a massive leadership role, if you perform it correctly,” the former official concluded.

Agency Reaction and Controversial Initiatives

Regarding inquiries about Dr. Høeg's fitness for the role and whether this appointment signifies more teamwork among FDA leaders on immunizations, a press secretary stated that the “questions are based on inaccurate assumptions”.

“This background is consistent with the duties of her position,” the spokesperson stated, citing the months Dr. Høeg spent advising the agency head on “medication safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg takes over the agency head's new expedited review system, a disputed one-day drug-approval program that reportedly worried her predecessors. “By what process are these medications being picked for this expedited pathway? Who is making the calls?” Dr. Howard said. “There is a lot of lack of transparency occurring at the agency right now.”

Broadly speaking, he said, “the FDA appears to be shifting towards more relaxed regulations of all drugs, aside from vaccines.”

Public Track Record on Vaccines

With vaccines, Dr. Høeg has a more established, if troubling, track record, some experts observe. She published a research paper using non-validated public submissions to assess the frequency of heart inflammation following COVID-19 immunization. She advised the Florida top health official Dr. Joseph Ladapo, who was said to have altered data to suggest Covid vaccines are pose a greater threat than they are.

Among her “desired changes” for the incoming administration featured altering rules for novel immunizations and ending “optional” vaccines, she stated after the election on a audio program. At the agency, Dr. Høeg has allegedly proposed preventing adolescent males from receiving Covid vaccines.

“She is an thorough ideologue who commences with her beliefs and reverse-engineers to accommodate the data in a very disingenuous, dishonest fashion,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg joined other dissenters, {like|